Analytical Data
-
基因名
ALK
- Application
-
别名
CD246; TFG/ALK; Ki1; Anaplastic Lymphoma Receptor Tyrosine Kinase
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UM73
-
表达区间
Met1348~Ser1611
-
分子量
36kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on ALK (anaplastic lymphoma kinase) recombinant proteins has gained significant attention in recent years due to their critical role in various cancers, particularly in anaplastic large cell lymphoma and non-small cell lung cancer (NSCLC). ALK is a receptor tyrosine kinase that, when mutated or rearranged, contributes to oncogenesis via constitutive activation of signaling pathways that promote cell proliferation and survival. Advances in molecular biology have enabled the identification of ALK gene fusions with other genes, leading to the production of oncogenic fusion proteins that drive tumorigenesis. This has spurred the development of targeted therapies, such as ALK inhibitors, which have shown promise in clinical trials and transformed treatment paradigms for ALK-positive cancers. Research into ALK recombinant proteins not only aids in understanding the structure-function relationships of these proteins and their role in cancer biology but also provides insights into resistance mechanisms against ALK inhibitors. Such studies are crucial for optimizing therapeutic strategies and improving patient outcomes, emphasizing the need for continued exploration of ALK's biology and its implications in cancer treatment.
